{"id":"experimental-snf472","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypocalcemia"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Vomiting"},{"rate":null,"effect":"Diarrhea"}]},"_chembl":{"chemblId":"CHEMBL4802218","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"SNF472 works by allosterically activating the calcium-sensing receptor on the surface of cells, which leads to decreased secretion of parathyroid hormone and reduced serum phosphate concentrations. This mechanism is particularly relevant in hemodialysis patients where hyperphosphatemia is a significant clinical problem associated with cardiovascular complications and mortality.","oneSentence":"SNF472 is a calcimimetic agent that binds to and activates the calcium-sensing receptor to reduce serum phosphate levels in patients with chronic kidney disease.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:11:59.634Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hyperphosphatemia in patients with chronic kidney disease on hemodialysis"}]},"trialDetails":[{"nctId":"NCT04195906","phase":"PHASE3","title":"Phase 3 Study of SNF472 for Calciphylaxis","status":"COMPLETED","sponsor":"Sanifit Therapeutics S. A.","startDate":"2020-02-12","conditions":"Calciphylaxis, Calcific Uremic Arteriolopathy","enrollment":71}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":7,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Experimental: SNF472","genericName":"Experimental: SNF472","companyName":"Sanifit Therapeutics S. A.","companyId":"sanifit-therapeutics-s-a","modality":"Small molecule","firstApprovalDate":"","aiSummary":"SNF472 is a calcimimetic agent that binds to and activates the calcium-sensing receptor to reduce serum phosphate levels in patients with chronic kidney disease. Used for Hyperphosphatemia in patients with chronic kidney disease on hemodialysis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}